Inventor · disambiguated record
Sara Jean Buhrlage
Also filed as: BUHRLAGE SARA · BUHRLAGE SARA JEAN
19 granted patents·12 pending applications·38 citations·filing 2009–2022
91Inventor score
Files withDANA FARBER CANCER INST INC27BUHRLAGE SARA1LEE PATRICK C1MASSACHUSETTS INST TECHNOLOGY1PENG LEE F1
Top patents by PatentIndex Score
31 records- 0189US9856223B2Methods to treat lymphoplasmacytic lymphomaDANA FARBER CANCER INST INC·Filed 2014·Granted Jan 2, 2018·6 cites·23 claims
- 0285US10112957B2Thiazolyl-containing compounds for treating proliferative diseasesDANA FARBER CANCER INST INC·Filed 2015·Granted Oct 30, 2018·5 cites·35 claims
- 0384US10525060B2HCK as a therapeutic target in MYD88 mutated diseasesDANA FARBER CANCER INST INC·Filed 2017·Granted Jan 7, 2020·5 cites·15 claims
- 0484US10450281B1Compounds and methods for treating cancerDANA FARBER CANCER INST INC·Filed 2017·Granted Oct 22, 2019·3 cites·20 claims
- 0583US11136409B2Compositions and methods for identification, assessment, prevention, and treatment of AML using USP10 biomarkers and modulatorsDANA FARBER CANCER INST INC·Filed 2017·Granted Oct 5, 2021·2 cites·8 claims
- 0683US9908872B2Methods to treat lymphoplasmacytic lymphomaDANA FARBER CANCER INST INC·Filed 2014·Granted Mar 6, 2018·6 cites·26 claims
- 0781US10633348B2Methods to treat lymphoplasmacytic lymphomaDANA FARBER CANCER INST INC·Filed 2017·Granted Apr 28, 2020·1 cites·29 claims
- 0880US10464949B2Thiazolyl-containing compounds for treating proliferative diseasesDANA FARBER CANCER INST INC·Filed 2018·Granted Nov 5, 2019·2 cites·32 claims
- 0978US9725425B1Compounds and methods for treating cancerDANA FARBER CANCER INST INC·Filed 2015·Granted Aug 8, 2017·2 cites·16 claims
- 1073US10597387B2Methods to treat lymphoplasmacytic lymphomaDANA FARBER CANCER INST INC·Filed 2018·Granted Mar 24, 2020·1 cites·30 claims
- 1169US11465983B2USP7 inhibitors for treating multiple myelomaDANA FARBER CANCER INST INC·Filed 2018·Granted Oct 11, 2022·1 cites·21 claims
- 1269US8530456B2Sonic hedgehog modulatorsPENG LEE F·Filed 2009·Granted Sep 10, 2013·4 cites·30 claims
- 1365USRE50030EMethods to treat lymphoplasmacytic lymphomaDANA FARBER CANCER INST INC·Filed 2014·Granted Jul 2, 2024·0 cites·33 claims
- 1461US2023265070A1Novel usp7 inhibitors for treating multiple myelomaDANA FARBER CANCER INST INC·Filed 2022·Application pending·0 cites
- 1559US10844077B2Thiazolyl-containing compounds for treating proliferative diseasesDANA FARBER CANCER INST INC·Filed 2019·Granted Nov 24, 2020·0 cites·27 claims
- 1658US2024299393A1Small molecule disruptors of protein interactions in histone deacetylase complexesDANA FARBER CANCER INST INC·Filed 2022·Application pending·0 cites
- 1757US2024335427A1Small molecule inhibition of deubiquitinating enzyme josephin domain containing 1 (josd1) as a targeted therapy for leukemias with mutant janus kinase 2 (jak2)DANA FARBER CANCER INST INC·Filed 2022·Application pending·0 cites
- 1856US2024376076A1Inhibitors targeting ubiquitin specific protease 7 (usp7)DANA FARBER CANCER INST INC·Filed 2022·Application pending·0 cites
- 1955US2023271918A1Substituted 3-amino-4-methylbenzenesulfonamides as small molecule inhibitors of ubiquitin-specific protease 28DANA FARBER CANCER INST INC·Filed 2021·Application pending·0 cites
- 2053US2023265082A1Substituted 1,2,4-oxadiazoles as small molecule inhibitors of ubiquitin-specific protease 28DANA FARBER CANCER INST INC·Filed 2021·Application pending·0 cites
- 2153US2023365583A1Fused tricyclic pyrimidine-thieno-pyridine small molecule inhibitors of ubiquitin-specific protease 28DANA FARBER CANCER INST INC·Filed 2021·Application pending·0 cites
- 2253US2023339865A1Quinazoline-derived hck inhibitors for use in the treatment of myd88 mutated diseasesDANA FARBER CANCER INST INC·Filed 2021·Application pending·0 cites
- 2352US2014094462A1Sonic hedgehog modulatorsBUHRLAGE SARA·Filed 2013·Application pending·0 cites
- 2451US2022372017A1Hck degraders and uses thereofDANA FARBER CANCER INST INC·Filed 2020·Application pending·0 cites
- 2549US2023203485A1Methods for modulating mhc-i expression and immunotherapy uses thereofLEE PATRICK C·Filed 2021·Application pending·0 cites
- 2646US2016046590A1Sonic hedgehog modulatorsMASSACHUSETTS INST TECHNOLOGY·Filed 2015·Application pending·0 cites
- 2745US12503453B2USP7 inhibitionDANA FARBER CANCER INST INC·Filed 2019·Granted Dec 23, 2025·0 cites·18 claims
- 2843US11447467B2Compounds for the degradation of STK4 and treatment of hematologic malignanciesDANA FARBER CANCER INST INC·Filed 2018·Granted Sep 20, 2022·0 cites·20 claims
- 2941US10975055B2Inhibitors of interleukin-1 receptor-associated kinases and uses thereofDANA FARBER CANCER INST INC·Filed 2017·Granted Apr 13, 2021·0 cites·20 claims
- 3035US10710978B2STK4 inhibitors for treatment of hematologic malignanciesDANA FARBER CANCER INST INC·Filed 2016·Granted Jul 14, 2020·0 cites·24 claims
- 3132US11136291B2Antifungal compounds and uses thereofDANA FARBER CANCER INST INC·Filed 2017·Granted Oct 5, 2021·0 cites·39 claims
Join the waitlist — get patent alerts
Get an alert when Sara Jean Buhrlage files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →